Best Law Firm Advertising Podcasts (2025)

1
Does E6 (R3) Blur the Line Between GCP and Privacy Laws? 1:37

43m ago1:37

1:37

In this video, Edye Edens discusses the recent transition of ICH GCP E6 from R2 to R3, highlighting an interesting question she received: Is R3 evolving into a privacy doctrine? Given its increased focus on data protection, system validation, and privacy responsibilities, some wonder if it overlaps with regulatory frameworks like HIPAA, especially …

1
RFK Jr. Confirmed as HHS Secretary: What It Means for Healthcare Policy 8:01

41m ago8:01

8:01

Edye Edens and Darshan Kulkarni dive into the confirmation of RFK Jr. as Secretary of Health and Human Services and the immediate impact of President Trump’s latest executive order. The order mandates a comprehensive national health assessment, addressing issues like obesity, diabetes, and pediatric disorders, and aims to reshape the country’s appr…

1
Stop Wasting Time, Start Scaling: 3 Ways to Automate NOW 12:37

23h ago12:37

12:37

Stop Wasting Time, Start Scaling: 3 Ways to Automate NOW This episode explores how legal marketing automation can save time, reduce errors, and improve client experiences in law firms. We discuss strategies for streamlining client intake, automating email campaigns, and scheduling social media posts to maintain consistency and engagement. Subscript…

1
America’s Research Future in Jeopardy 7:44

3d ago7:44

7:44

Darshan Kulkarni and Edye Edens break down the significant impact of the Trump administration’s decision to cut NIH funding and reduce agency workforces, including the FDA, OHRP, and other key regulatory bodies. They discuss how these cuts could lead to serious disruptions in research funding, approval timelines, and the overall pace of medical inn…

1
Trump Administration’s NIH cuts: Will they cripple US medical research? 7:48

4d ago7:48

7:48

Darshan Kulkarni and Edye Edens discuss the recent controversy surrounding the Trump administration’s decision to cap NIH overhead funding (also known as indirect costs or F&A) at 15%. This sweeping change has already sparked significant backlash, with academic medical centers, particularly in Democratic states, filing lawsuits to challenge the pol…

1
DEI Under Trump: What It Means for Clinical Trials 7:47

5d ago7:47

7:47

The Trump administration’s early actions have significantly impacted federally funded programs, particularly in the clinical trial space, by rolling back diversity, equity, and inclusion (DEI) initiatives. This shift raises serious concerns for scientific research, as diversity in clinical trials ensures that drugs and devices are effective across …

1
Scale Your Law Firm to $15M+ with Brian LaBovick 35:06

6d ago35:06

35:06

Send us a text Join Sasha Berson as he speaks with Brian LaBovick, Founder of LaBovick Law Group 👉 Sasha and Brian explore: — The biggest hiring mistakes law firm owners make and how to build a high-performing team. — The key marketing investments that helped Brian scale his firm to $15M+ in revenue. — How operational systems and processes are esse…

1
CAPA & RCA: A Must for Pharma M&A 1:39

6d ago1:39

1:39

When acquiring a pharmaceutical company, evaluating its quality and compliance programs is crucial. A strong program starts with well-documented policies and procedures, followed by comprehensive training to ensure employees understand and follow them. However, having policies in place isn’t enough—regulatory bodies like the FDA and DOJ stress that…

1
Trump Targets Indirect Costs in NIH Funding 1:21

7d ago1:21

1:21

On Friday, the Trump administration announced a 15% cap on NIH indirect costs, raising important questions about its impact on research funding. Edye Edens breaks down what this means, clarifying that while direct costs like salaries and equipment remain unchanged, the cap affects crucial behind-the-scenes expenses such as lab maintenance, IT infra…

1
The USAID Halt and Its Consequences for Clinical Research 2:29

8d ago2:29

2:29

The Trump administration’s actions have effectively halted USAID-funded clinical research worldwide, creating an unprecedented situation with significant ethical, legal, and medical implications. Clinical trials that relied on USAID funding have stopped, leaving ongoing research in limbo and raising serious concerns about what happens to trial part…

1
Law Firm Ads That Don't Look Like Ads 13:42

8d ago13:42

13:42

Law Firm Ads That Don't Look Like Ads Ever wondered why your law firm's advertisements aren't hitting the mark? Join our host, Toby Rosen, as we reveal innovative marketing strategies designed to break through ad fatigue and build genuine connections with potential clients. Traditional ads often fall short, triggering resistance by their very natur…

1
Ebola Vaccine Trial in Record Time! 2:29

10d ago2:29

2:29

On January 30, 2025, Uganda confirmed an outbreak of the Ebola Sudan virus, and in an unprecedented global first, a clinical trial to assess the efficacy of a vaccine against the virus was launched within just four days. This rapid response was made possible by proactive planning following a 2022 outbreak, during which the Ugandan Ministry of Healt…

1
Your Clinical Trial Site M&A Agreement is Exposing You to Risk 0:50

11d ago0:50

0:50

When working on an M&A transaction involving a clinical trial site, it's crucial to thoroughly review vendor agreements. It's not just about what is included, but what is missing. For example, do you have the right quality and privacy agreements in place, or are you unknowingly exposing yourself to liability? If there’s a lack of necessary agreemen…

1
Build a $1M+ Legal Tech Startup in 18 Months - Insights from Karl Seelbach 31:22

13d ago31:22

31:22

Send us a text Join Sasha Berson as he speaks with Karl Seelbach, Co-founder of Scribe and Managing Partner at Doyle & Seelbach 👉 Sasha and Karl explore: — Why the traditional court reporting model hasn’t changed in over 150 years and is ripe for disruption. — Insights into starting and scaling a legal-tech startup to seven figures in just over a y…

1
What Does ICH E6 R3 Say About Returning Data to Participants? 1:01

13d ago1:01

1:01

The most recent ICH E6(R3) final guidance introduces critical updates to Good Clinical Practice (GCP), particularly around informed consent and participant data access. The guidance emphasizes greater flexibility and the use of technology-driven innovations to enhance how patients understand what they are consenting to. A significant update appears…

1
Navigating the Ongoing HHS Communication Freeze 2:28

14d ago2:28

2:28

Now that we’ve passed February 1st, a key date for the potential easing of the freeze on all HHS communications, we find ourselves at February 3rd with no significant updates or changes. Despite expectations that restrictions might begin to lift, there has been no broad release of communications across federal agencies involved in clinical trials a…

1
Ordinary People Are Changing Medicine 3:47

15d ago3:47

3:47

Citizen biohacking is an empowering movement where individuals take medical innovation into their own hands, often stepping in when traditional medicine falls short. Driven by necessity, love, and a desire for survival, many have solved complex medical problems themselves, leading to groundbreaking discoveries. This trend raises important questions…

1
🔒 Transform Your Small Law Firm's Marketing with Free and Low-Cost Digital Tools 16:34

15d ago16:34

16:34

Subscriber-only episode Small law firms can compete effectively in marketing without a large budget by leveraging strategic, low-cost tools and community connections. This episode reveals actionable insights into utilizing online resources, enhancing client relationships through testimonials, and the power of social media engagement. • Emphasis on …

1
Trump’s First 10 Days: The Impact on Clinical Trials 2:29

18d ago2:29

2:29

Edye Edens discusses how the first nine to ten days under the new administration have brought notable shifts for both healthcare and clinical research, particularly in regulatory compliance and funding. While remaining politically neutral, the focus is on understanding how these changes impact clinical trials and research oversight. A key update is…

1
Selling a Business with Issues 0:58

18d ago0:58

0:58

When selling a company, certain issues may arise that could concern potential buyers. Here's a breakdown of how to approach them: Price Adjustments: Some issues can be acknowledged, and the buyer may adjust the price accordingly, allowing the sale to proceed with minimal adjustments. Successor Liability: Issues like DOJ concerns or successor liabil…

1
How Attorneys Can Gain More Clients and Credibility with a Book – Insights from Melanie Herschorn 26:38

20d ago26:38

26:38

Send us a text Join Sasha Berson as he speaks with Melanie Herschorn, Founder of Big Impact Books 👉 Sasha and Melanie explore: — Why writing a book can be a game-changer for attorneys and how it bridges the gap between legal jargon and client understanding. — The misconceptions attorneys have about self-publishing and how to protect their intellect…

1
Breaking Down GCP E6(R3) 11:44

21d ago11:44

11:44

Darshan Kulkarni and Edye Edens discuss the latest update to Good Clinical Practice (GCP) guidelines, E6 R3, was explored. GCP, developed by the International Council for Harmonisation (ICH), provides globally accepted ethical and operational standards for conducting clinical trials. The 2025 update represents a significant revision since its last …

1
Maximizing Your Law Firm's Online Potential with WordPress 18:21

22d ago18:21

18:21

Pros & Cons of WordPress for Law Firms Choosing WordPress for your law firm's website involves weighing significant benefits against notable drawbacks. While its flexibility, SEO options, and cost-effectiveness are appealing, learning curves, security risks, and performance issues demand careful consideration. • Exploration of WordPress's benefits …

1
AdvaMed 7 rules for Essential AI Innovation 5:54

24d ago5:54

5:54

Artificial intelligence (AI) is rapidly reshaping healthcare, with over 950 FDA-authorized AI devices transforming diagnosis, treatment, and administrative workflows. AdvaMed's new position paper emphasizes seven foundational principles to guide AI in medical technology development and regulation. Key Highlights: A Robust Regulatory Framework: Adva…

1
18 Minutes to More Referrals: Ben Paul’s Proven Formula for Lawyers 48:28

27d ago48:28

48:28

Send us a text Join Sasha Berson as he speaks with Ben Paul, Founder of BD Ladder 👉 Sasha and Ben explore: — The surprising impact of spending just 18 minutes daily on business development, adding up to over 70 hours a year of focused growth. — Why starting business development early in your career is a game-changer. — Strategies to overcome fear o…

1
Teva’s Case Should Shape Your Pharma Strategy 1:21

27d ago1:21

1:21

Teva Pharmaceutical's $450 million settlement highlights the challenges of compliance in the pharmaceutical industry. The Department of Justice accused Teva of violating the anti-kickback statute and the False Claims Act by using co-payment assistance programs to steer Medicare payments for its drug Copaxone while raising prices. Additionally, Teva…

1
🔒 AI’s Impact on Healthcare: Liability, Ethics, and Responsibility 8:10

28d ago8:10

8:10

Subscriber-only episode Today, we explore a pressing issue in the healthcare landscape: the liability associated with artificial intelligence (AI). As AI technologies transform healthcare—from diagnostic tools to treatment recommendations—it's crucial to understand the legal and ethical implications surrounding their use, particularly regarding acc…

1
Stop Copying Everyone Else; Create Your Own Damn Strategy 16:32

29d ago16:32

16:32

Stop Copying Everyone Else; Create Your Own Damn Strategy This episode encourages law firms to stop copying competitors and instead create unique marketing strategies that reflect their individual strengths. It explores the importance of authenticity, understanding client needs, and implementing a sustainable framework for successful marketing. • D…

1
Four Types of Research related Grant Fraud 4:56

1M ago4:56

4:56

Grant fraud encompasses four critical issues that can have severe repercussions for institutions and individuals. 1. Foreign Influence and Funding: Failing to disclose foreign government support, as seen in Ohio State University's $875,000 settlement (November 2022). Similar allegations against U Ming Qing Xiao in the Southern District of Illinois …

1
Defining Scope in Due Diligence Transactions 0:53

1M ago0:53

0:53

When conducting due diligence for a life sciences company, it's essential to align the scope with the transaction's objectives. Key considerations include: Transaction Purpose: Determine if the goal is asset divestiture, strategic acquisition, or another objective. Regulatory Compliance: Assess adherence to industry regulations, including FDA guide…

1
Clinical Trial Checklist 7:33

1M ago7:33

7:33

Darshan Kulkarni and Edye Edens discuss the essential steps for launching a clinical trial site, emphasizing the importance of navigating both state-specific regulations and the logistics involved. They begin by highlighting the critical role of informed consent and legal authority, which vary across states. In particular, states like Texas and Cal…

1
Learn Legal Advertising Hacks from Harlan Schillinger [125+ Law Firms Transformed!] 49:41

1M ago49:41

49:41

Send us a text Join Sasha Berson as he speaks with Harlan Schillinger, Legal Marketing Expert at Harlan Schillinger 👉 Sasha and Harlan explore: — The challenges and triumphs of producing the first-ever TV commercials for lawyers in 1979. — The evolution of legal advertising, from the early days of answering countless calls from TV ads to today's fo…

1
Presidential Changes and Impact on Drug Related Misinformation 11:28

1M ago11:28

11:28

Misinformation around vaccines and treatments isn’t new, but with figures like Robert F. Kennedy Jr. in the spotlight, how should regulatory agencies respond? There will be potential changes coming to the FDA and public health regulations with the new administration. Historical transitions, such as the one from the Obama administration to the Trump…

1
Your 2025 Marketing Plan 19:17

1M ago19:17

19:17

Your 2025 Marketing Plan We explore the essential steps to understanding client origins, maximizing ROI, and aligning your strategies with the firm's ambitions. Toby offers insights into using AI-driven tools for everything from email automation to refining client interactions, ensuring your firm stays ahead in the competitive landscape. Step behin…

1
Prep for Selling Your Company! 4:10

1M ago4:10

4:10

When preparing to sell your pharmaceutical company, particularly with a Phase 1 product, it’s essential to assess potential buyers and ensure readiness. Darshan’s Insights: When preparing to sell your pharmaceutical company, it’s crucial to evaluate potential buyers and readiness. Key factors include: 1. Compliance Programs: Ensure adherence to OIG…

1
Top Tips for Starting a Clinical Trial Site 6:00

1M ago6:00

6:00

Launching a clinical trial site is an exciting opportunity, but it comes with important legal, regulatory, and operational challenges. Darshan Kulkarni Says: Starting a clinical trial site is an exciting step, but it requires careful planning to address key legal and regulatory considerations. Privacy compliance is a major factor—going beyond HIPAA…

1
When Drug Reps Visit: Darshan Reacts 4:27

1M ago4:27

4:27

Darshan reacts to a fake interaction between a drug sales representative and a doctor. He shares insights on pharmaceutical marketing tactics, highlighting that while doctors often find sales reps personable, they may not trust them as much as medical science liaisons (MSLs) due to limitations on what reps can legally discuss about drugs. Darshan e…

1
Instagram Strategy for Lawyers to Hit 250K Followers from Joe McCarthy 31:40

1M ago31:40

31:40

Send us a text Join Sasha Berson as he speaks with Joe McCarthy, Founder of JEM Social 👉 Sasha and Joe explore: — The importance of authentic content and messaging over superficial production quality. — Practical strategies for creating a content calendar and consistent posting schedule. — How investing strategically in your social media presence c…

1
Is Pfizer competing with your pharmacy? 2:29

1M ago2:29

2:29

Pharmaceutical companies, like Pfizer, are venturing into digital healthcare platforms, raising questions about competition with traditional pharmacies. Pfizer recently announced its initiative, "Pfizer for All," a digital platform that offers services such as vaccine scheduling and potential savings on medications, possibly bypassing pharmacy bene…

1
Talking to a Functional Medicine Doctor 23:54

1M ago23:54

23:54

In this episode, guest host Kate Woods interviews Jessica Miller, who shares her journey with functional medicine, highlighting its focus on addressing root causes of illness through personalized, lifestyle-based approaches. They discuss its challenges, benefits, and empowering patients to take charge of their health. Functional medicine focuses on…

1
🔒 Why Every Lawyer Needs a Content Strategy, and How to Create One 18:52

1M ago18:52

18:52

Subscriber-only episode Why Every Lawyer Needs a Content Strategy, and How to Create One What if you could craft a legal content strategy as effective as your courtroom tactics? Join me, Toby Rosen, as we discover the power of a well-structured content plan. Just like a lawyer meticulously prepares for a major trial, creating a comprehensive conten…

1
🔒 Leveraging AI and RWD to Reshape Drug Trials! 5:17

2M ago5:17

5:17

Subscriber-only episode In this episode, Darshan explores how artificial intelligence (AI) is transforming clinical trial design, with a focus on using real-world data (RWD). The episode dives into the FDA’s recognition of AI’s potential to enhance clinical trials by using data from electronic health records (EHRs), medical claims, and disease regi…

1
DCTs in Oncology: Can They Work? 12:04

2M ago12:04

12:04

The FDA’s 2024 guidance on decentralized clinical trials (DCTs) has the potential to transform clinical research, particularly in oncology. While many still view DCTs as either fully virtual or fully in-person, the guidance promotes a hybrid approach, blending traditional and decentralized elements. This flexibility may help smaller sites participa…

1
Marketing Due Diligence in Stem cell M&A Transactions 6:35

2M ago6:35

6:35

The stem cell industry is growing rapidly but faces heightened regulatory scrutiny, particularly regarding marketing practices. Recent events highlight this issue: Rebecca Tushnet's blog on state "Little FTC Acts" emphasizes their enforcement power against deceptive marketing, and the guilty plea of a stem cell product manufacturer’s CEO for fraud …

1
Why Are PBMs Blocking Your Meds? - Darshan reacts 4:10

2M ago4:10

4:10

In this episode, Darshan reacts to how at the start of each year, pharmacists often face the challenge of informing patients that their medications are no longer covered due to formulary changes managed by Pharmacy Benefit Managers (PBMs). PBMs, who work for insurance companies, negotiate drug prices and determine which medications are covered, oft…

1
Misleading Ads: Ad laws and Consumer Protection for Marketers 14:10

2M ago14:10

14:10

Rebecca Tushnet discusses the potential explores the implications of misleading advertisements, particularly concerning pregnancy clinics. Even true statements can be disparaging if they mislead consumers. Cases like the California lawsuit questioning the use of "Dr." titles. Tushnet examines when products like milk can be labeled as such and scrut…

1
Title: How Ben Leader Boosted Conversions from 50 to 80% and Quadrupled Case Volume 48:51

2M ago48:51

48:51

Send us a text Join Sasha Berson as he speaks with Ben Leader, Partner at Elrod Pope Law Firm 👉 Sasha and Ben explore: — The pivotal role of joining mastermind groups to accelerate firm growth. — How shifting focus from practicing law to marketing and intake management transformed Ben’s law firm. — Strategies to optimize marketing spending for bett…

1
5 Common Clinical Trial Site Failures 1:07

2M ago1:07

1:07

Darshan discusses the five most common clinical trial site issues: 1. Failure to Follow Investigational Plan: Treating clinical trials like routine medical practice instead of strictly following the protocol can lead to serious issues. 2. Inadequate and Inaccurate Records: The FDA emphasizes that if it’s not documented, it didn’t happen. Inaccurate…

1
Faster FDA Recalls 4:06

2M ago4:06

4:06

The FDA’s Center for Devices and Radiological Health (CDRH) has launched a groundbreaking initiative aimed at improving the efficiency and speed of recall communications for medical devices. Here are the five key strategies from the FDA's new medical device recall initiative: Faster Alerts for High-Risk Devices: The FDA aims to reduce the time betw…

Podcasts Worth a Listen

Law Firm Advertising Podcasts

Podcasts Worth a Listen

Quick Reference Guide

zproxy.org